Lunai Bioworks Inc.
LNAINASDAQHealthcareBiotechnology
Previous close
$2.155
−$0.045 · -2.05%
LNAI company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
8
Overpriced
Momentum
30
Weakening
Sentiment
54
Mixed
Risk resilience
37
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteLunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- David H. Weinstein
- Listed since
- Sep 30, 2025
- Employees
- 29
Market position
Day range
Current $2.155
52-week range
Current $2.155
- Open
- $2.25
- Previous close
- $2.20
- Volume
- 25.83K
- 0.03× average
- Average volume
- 972.56K
- Average daily volume
- Market cap
- 9.77M USD
- Beta
- 0.32
- Market reference 1
- 50-day average
- $2.7269
- -20.97% below average
- 200-day average
- $4.5985
- -53.14% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 47.71M USD
- P/E (TTM)
- -0.04×
- P/B (TTM)
- -0.7×
- P/S (TTM)
- 466.55×
- EV / EBITDA
- -0.27×
- Earnings yield
- -472.99%
- Free cash flow yield
- -20.92%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- -360.71%
- Operating margin
- -46991.97%
- Net margin
- -612568.11%
- Return on equity
- 833.76%
- Return on assets
- -2162.69%
- Return on invested capital
- 165.94%
Financial health
- Debt / equity
- -0.15×
- Current ratio
- 0.04×
- Altman Z-score
- -117.01
- Piotroski F-score
- 4 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Cost of goods sold | 129.09K USD | — | — | — | 391.42K USD |
| Gross profit | −129.09K USD | — | — | — | −391.42K USD |
| Research and development | 537.43K USD | 2.71M USD | 4.17M USD | 8.37M USD | 15.54M USD |
| Selling, general, and administrative | 17.88M USD | 24.56M USD | 15.32M USD | 14.33M USD | 7.47M USD |
| Operating expenses | 18.42M USD | 81.64M USD | 38.56M USD | 116.08M USD | 23.01M USD |
| Interest income | 116.35K USD | — | — | 122.04K USD | 13.18K USD |
| Interest expense | 725.68K USD | 2.43M USD | 706.96K USD | 372.84K USD | 379.61K USD |
| Depreciation and amortization | 129.1K USD | 121.86K USD | 113.5K USD | 123.59K USD | 391.42K USD |
| Operating income | −18.55M USD | −81.64M USD | −38.56M USD | −116.08M USD | −23.4M USD |
| Net income | −178.01M USD | −88.43M USD | −39.68M USD | −113.43M USD | −26.72M USD |
Company facts updated Aug 24, 2026.
LNAI peers
ETFs holding LNAI
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research LNAIresearch.disclaimer